Jan 31, 2025 / 08:00AM GMT
Hans Eid - Ultimovacs ASA - Chief Financial Officer
Good morning and welcome to this webcast where we will give a business update and present the results of Ultimovacs for the fourth quarter of 2024.
My name is Hans Eid and I'm the CFO and interim CEO of Ultimovacs. With me today. I have Namir Hassan, CEO of Zelluna Immunotherapy who will become the CEO of the new Cellular Group. Our Chief Medical Officer, Jens Bjorheim will also be available during the Q&A session. You may post questions during the presentation through the web platform for these webcasts.
Next slide please. As a listed company, we would like to share our disclaimer.
Next slide please. Today, I will go through the key even the last quarter, which is the business combination with Zelluna. I will also go through the key financials. Thereafter, Namir will give a more thorough presentation of the New Zelluna group with a particular focus on the core TCR and K technology.
Next slide please. And the next, thank you. On the 17 of December, we announced the business Combination transaction between
Q4 2024 Ultimovacs ASA Earnings Call Transcript
Jan 31, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers